TABLE 3

Attitudes and Barriers Regarding MM Use

All Providers (N = 288), Frequency (%)Providers Legally ETC for MM (n = 96), Frequency (%)Providers n-ETC for MM (n = 192), Frequency (%)Unadjusted OR (95% CI)Unadjusted PAdjusted Model NAdjusted ORa (95% CI)Adjusted Pa
Willing to help patients access MM240 of 261 (92)71 of 84 (85)169 of 177 (95)0.26 (0.1–0.65).00412440.61 (0.17–2.15).44
Approve of patients smoking MM133 of 234 (57)29 of 75 (39)104 of 159 (65)0.33 (0.19–0.59).00022190.25 (0.11–0.55).0005
Approve of patients using oral formulations of MM223 of 250 (89)56 of 76 (74)167 of 174 (96)0.12 (0.05–0.29)<.00012360.17 (0.05–0.53).0025
Approve of using MM as cancer-directed therapy158 of 236 (67)19 of 80 (24)139 of 156 (89)0.04 (0.02–0.08)<.00012220.04 (0.01–0.09)<.0001
Approve of using MM to manage symptoms236 of 258 (92)67 of 82 (82)169 of 176 (96)0.19 (0.07–0.47).00042440.16 (0.05–0.52).0026
Favor clinical trials investigating MM use in children237 of 256 (93)80 of 85 (94)157 of 171 (92)1.43 (0.5–4.1).51
Unconcerned about substance abuse among patients who receive MM162 of 259 (63)55 of 90 (61)107 of 169 (63)0.91 (0.54–1.54).73
Unconcerned about prosecution for helping patients access MM208 of 260 (80)75 of 91 (82)133 of 169 (79)1.27 (0.66–2.44).48
  • —, not included in model.

  • a In multivariate logistic regression, we compared ETC to n-ETC providers (reference group), adjusting for provider age, sex, race, and location of practice.